AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
- Japan, Australia shares hit record high on Wall Street bounce
- Nikkei 225 hits 40,000 as tech gains bring new record highs
- Oil rises, markets await OPEC+ decision amid mixed demand drivers
- Dollar steady as traders weigh Fed rate cut bets; yen shaky at 150/$
- Dell Q4 results top estimates on boost from AI-led server demand; shares jump
FILE PHOTO: The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron/File Photo
(Reuters) - Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.
The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. It did not say what kind of cancer they plan to target.
Absci and AstraZeneca did not immediately respond to a Reuters requests for comment.
The deal includes an upfront fee for Absci, research and development funding and milestone payments, as well as royalties on any product sales, the newspaper said.
Sean McClain, Absci’s founder and chief executive, was quoted as saying the application of engineering principles to drug discovery improved the potential of success and reduced time spent in development.
Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
(Reporting by Shivani Tanna in Bengaluru; Editing by William Mallard)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China's parliament to unveil more stimulus next week, bold reforms unlikely
- WTO talks run deep into overtime with no breakthrough in sight
- ExxonMobil, Shell to work with Singapore on carbon capture and storage project
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!